Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28193844 | 0.87 | HMGCR (0.47) | MAPTTDP1HMGCRPTPN1SMN1; SMN2 | |
| SCHEMBL6717832 | 0.84 | PDE4D (0.56) | MAPTTDP1HMGCRSMN1; SMN2LMNA | |
| SCHEMBL20007016 | 0.83 | HMGCR (0.56) | MAPTHMGCRPTPN1SMN1; SMN2KDM4E | |
| SCHEMBL27605516 | 0.83 | HMGCR (0.47) | HMGCRSMN1; SMN2HPGDSKDM4ERAB9A | |
| SCHEMBL27947398 | 0.82 | PTPN1 (0.56) | MAPTTDP1PTPN1SMN1; SMN2LMNA | |
| SCHEMBL27435238 | 0.82 | PDE4D (0.51) | PDE4DMEN1KMT2A | |
| SCHEMBL27982790 | 0.81 | MAPT (0.67) | MAPTTDP1HMGCRSMN1; SMN2LMNA | |
| SCHEMBL2337418 | 0.81 | MAPT (0.66) | MAPTTDP1PTPN1SMN1; SMN2KDM4E | |
| SCHEMBL11102155 | 0.81 | MAPT (0.54) | MAPTTDP1PTPN1SMN1; SMN2LMNA | |
| SCHEMBL24069248 | 0.80 | PDE4D (0.49) | MAPTTDP1HMGCRSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102146026-B | Protosappanin A derivative and preparation method and application thereof | UNIV HARBIN MEDICAL | 2013-04-24 | — | — | CN | disclosed |
| US-20120029216-A1 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | ERIMOS PHARMACEUTICALS LLC (US) | 2012-02-02 | — | — | US | disclosed |
| CN-102171173-A | Scalable synthetic process for making meso-1,4 - bis (3,4 - dimethoxyphenyl)-dimethyl butane | ERIMOS PHARMACEUTICALS LLC | 2011-08-31 | — | — | CN | disclosed |
| CN-102146026-A | Protosappanin A derivative and preparation method and application thereof | UNIV HARBIN MEDICAL | 2011-08-10 | — | — | CN | disclosed |
| EP-2318347-A2 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | Erimos Pharmaceuticals LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010014936-A2 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | ERIMOS PHARMACEUTICALS LLC (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | disclosed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988003806-A1 | PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029216-A1 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | PTGIS, PTGES, POR | MAPT 4613/4885TDP1 3529/4885HMGCR 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.